

Perrigo InvestorRoom

Perrigo Company Announces Tentative Approval for Famotidine Tablets

PRNewswire-FirstCall
ALLEGAN, Mich.

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Famotidine Tablets USP, 20 mg (OTC). Final approval is anticipated upon the expiration of the brand's new product exclusivity on September 23, 2006.

The product is equivalent to Merck Research Laboratories' Maximum Strength Pepcid® AC tablets, 20 mg, indicated for the relief and prevention of heartburn.

The Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, United Kingdom, Mexico and Germany. Visit Perrigo on the Internet (<http://www.perrigo.com/>).

SOURCE: Perrigo Company

CONTACT: Ernest J. Schenk, Manager, Investor Relations and Communication of Perrigo Company, +1-269-673-9212, or E-mail: eschenk@perrigo.com

Web site: <http://www.perrigo.com/>

<https://investor.perrigo.com/2005-09-12-Perrigo-Company-Announces-Tentative-Approval-for-Famotidine-Tablets>